BioHarvest Reports Third Quarter 2026 Financial Results and Provides Business Update

BioHarvest’s revenue and margins are falling, with losses widening and cash declining.

What the company is saying

BioHarvest Sciences Inc (NASDAQ:BHST, FSE:8MV0) is communicating a period of deliberate transition, emphasizing a shift toward cash preservation, selective investment, and a narrower commercial focus. The company frames its Q3 2026 results as a consequence of intentionally moderating lower-return customer acquisition and prioritizing profitability over top-line growth, particularly in the Products Business Unit. Management, led by CEO and Executive Chairman Dr. Zaki Rakib, highlights a strategy to grow the VINIA brand with better economics and to concentrate CDMO resources on projects with the clearest commercialization pathways, such as the fragrance compound, sweetener compounds with Tate & Lyle, and Saffron development. The announcement underscores the signing of a first manufacturing and supply agreement for a rare, high-value, plant-based fragrance ingredient, with production potentially starting as early as Q1 2027. The company also notes the launch of VINIA Daily Chews as part of its product expansion. The tone is measured, with explicit acknowledgment of revenue declines and margin compression, and a stated expectation that operational improvements and renewed growth will become evident in early 2027. The company is transparent about the need to align capital allocation and operating expenses with its most promising opportunities.

What the data suggests

The disclosed figures show a deteriorating financial trajectory. Q3 2026 revenue fell to $7.9 million from $8.8 million in Q2 2026 and $9.1 million in Q3 2025. Gross margin dropped to 54% from 58% in the prior quarter and 61% a year ago, reflecting a revenue mix shift away from higher-margin CDMO development. Operating loss widened to $3 million from $2.5 million in Q2 2026 and $0.9 million in Q3 2025. Net loss increased to $3.3 million, or $0.15 per share, versus $2.5 million and $0.14 per share a year earlier. Cash, cash equivalents, and bank deposits declined to $12.5 million at September 30, 2026, from $16.2 million at June 30 and $23 million at year-end 2025. R&D expenses rose to $1.8 million, driven by accelerated development for the fragrance supply agreement, while sales and marketing and G&A expenses remained elevated. Adjusted EBITDA loss for Q3 2026 was $2.0 million, with CDMO and Products divisions contributing $1.4 million and $0.6 million in losses, respectively. Full-year 2026 revenue guidance for VINIA D2C is now $31–$32 million, with consolidated revenue expected at $32–$33.5 million and an Adjusted EBITDA loss of $5.5–$7.5 million. The fragrance supply agreement is projected to generate $20–$30 million in revenue in 2027–2028, but this is contingent on successful execution and customer follow-through. The company’s disclosures are detailed for headline metrics but lack granular divisional breakdowns.

Analysis

The announcement is measured in tone and provides detailed, factual disclosure of deteriorating financial performance: revenue, gross margin, and cash are all declining, while losses are widening. Forward-looking statements (such as revenue guidance and the fragrance supply agreement) are present but are not exaggerated or promotional; they are supported by a signed agreement and realistic timelines (production potentially beginning as early as Q1 2027). The company is transparent about its challenges, including the need for cash preservation and selective investment. There is no evidence of narrative inflation or overstatement; the language is cautious, and the company even revises guidance downward. The gap between narrative and evidence is minimal, with most claims directly supported by disclosed figures. The only mild inflation is in the framing of strategic priorities and the potential of the fragrance agreement, but these are not overstated relative to the evidence.

Risk flags

• ●Liquidity risk is elevated, with cash, cash equivalents, and bank deposits falling from $23 million at December 31, 2025 to $12.5 million at September 30, 2026. Continued operating losses and negative Adjusted EBITDA increase the risk of further cash burn and potential need for external financing.
• ●Revenue and margin compression are persistent, with Q3 2026 revenue down year-over-year and gross margin declining from 61% to 54%. This trend suggests that the company’s transition to higher-quality revenue has not yet stabilized the business.
• ●Execution risk is high for the fragrance supply agreement, which is projected to generate $20–$30 million in 2027–2028 but depends on successful completion of development, timely scale-up, and customer performance. Any delays or failures could materially impact future revenue.
• ●The company’s reliance on a small set of advanced CDMO projects and a single major fragrance agreement concentrates risk, as setbacks in these areas could disproportionately affect overall performance.
• ●Guidance for VINIA D2C and CDMO revenue has been revised, and the company acknowledges that further revisions may be necessary if operational improvements or customer acquisition do not materialize as planned.

Bottom line

BioHarvest Sciences is facing worsening financials, with declining revenue, shrinking margins, and rising losses across both its Products and CDMO business units. The company is taking defensive actions—cutting costs, narrowing its focus, and slowing investment—to preserve cash, but its cash position has already fallen sharply over the past nine months. The new fragrance supply agreement could provide a significant revenue boost in 2027–2028, but this is not guaranteed and depends on flawless execution and customer demand. Near-term results are likely to remain weak, with management only expecting operational improvements and renewed growth to become visible in early 2027. Investors should watch for evidence of a turnaround in VINIA sales, successful delivery on the fragrance contract, and stabilization of cash burn. The most important takeaway is that BioHarvest’s current trajectory is negative, and the company’s future now hinges on a small number of high-stakes projects and its ability to stem ongoing losses.

Announcement summary

(NASDAQ:BHST) (FSE:8MV0) BioHarvest Sciences Inc reported financial results for the three and nine months ended September 30, 2026, and outlined its strategic priorities for 2027. Q3 2026 revenue was $7.9 million, down from $8.8 million in Q2 2026 and $9.1 million in Q3 2025, reflecting a deliberate moderation of lower-return customer acquisition in the Products Business Unit and the timing of CDMO development revenue. Gross margin for Q3 2026 was 54%, compared to 58% in Q2 2026 and approximately 61% in Q3 2025, due to a revenue mix weighted toward Products and a lower contribution from higher-margin CDMO development revenue. Operating loss was $3 million, compared with $2.5 million in Q2 2026 and $0.9 million in Q3 2025. Cash, cash equivalents and bank deposits totaled $12.5 million at September 30, 2026, versus $16.2 million at June 30, 2026 and $23 million at December 31, 2025. The company is focusing on cash preservation, controlled VINIA growth, and concentrating CDMO resources on select programs with the clearest commercial and manufacturing pathways. In August, BioHarvest signed the CDMO division's first manufacturing and supply agreement, an exclusive agreement covering the scaled production of a rare, high-value, plant-based fragrance ingredient, with a UAE-based customer. The agreement provides for the production of an anticipated 20 tons of the fragrance composition, with limited production potentially beginning as early as Q1 2027. In September, BioHarvest launched single-dose VINIA Daily Chews to broaden consumer choice and provide an additional pathway for customer acquisition and revenue growth. Cost of revenue for Q3 2026 was $3.6 million, compared to $3.5 million for the same period last year. Gross profit in Q3 2026 was $4.2 million, or 54% of total revenue, compared to $5.6 million, or 61% of total revenue, in Q3 2025. R&D expenses totaled $1.8 million for Q3 2026, compared to $1.4 million for Q3 2025, primarily due to higher technology development expenditures within the CDMO Services Business Unit. Sales and marketing expenses were $4.0 million for Q3 2026, compared to $4.1 million for Q3 2025. G&A expenses were $1.5 million for Q3 2026, compared to $0.9 million for Q3 2025, with the increase primarily reflecting one-time income of $0.4 million recognized in Q3 2025. Net loss for Q3 2026 was $3.3 million, or $0.15 per basic and diluted share, compared to a net loss of $2.5 million, or $0.14 per basic and diluted share, for Q3 2025. Adjusted EBITDA loss was $2.0 million, compared to $0.4 million in Q3 2025. Under the two-lens approach, Q3 2026 Adjusted EBITDA losses of the CDMO services and Products divisions were $1.4 million and $0.6 million respectively, compared to $0.2 million and $0.2 million in Q3 2025. Full-year revenue guidance for the VINIA D2C business has been revised to $31-$32 million, while Adjusted EBITDA loss guidance remains unchanged at $1.5-$2.5 million. The 20-ton plant-based fragrance supply agreement is estimated to generate revenue of $20-$30 million in 2027-2028. The CDMO business has revised its expected full-year revenue range to $1-$1.5 million and now anticipates a full-year Adjusted EBITDA loss of $4-$5 million. On a consolidated basis, the company now expects full-year 2026 revenue of $32-$33.5 million and an Adjusted EBITDA loss in the range of $5.5-$7.5 million. The company will hold its Q3 2026 earnings call on November 12, 2026 at 8:00 a.m. Eastern Time.

Disagree with this article?